{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T17:43:04Z","timestamp":1783618984468,"version":"3.55.0"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T00:00:00Z","timestamp":1704931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Apical hypertrophic cardiomyopathy (ApHCM) is a subtype of hypertrophic cardiomyopathy (HCM) that affects up to 25% of Asian patients and is not as well understood in non-Asian patients. Although ApHCM has been considered a more \u201cbenign\u201d variant, it is associated with increased risk of atrial and ventricular arrhythmias, apical thrombi, stroke, and progressive heart failure. The occurrence of pulmonary hypertension (PH) in ApHCM, due to elevated pressures on the left side of the heart, has been documented. However, the exact prevalence of PH in ApHCM and sex differences remain uncertain.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We sought to evaluate the prevalence, risk associations, and sex differences in elevated pulmonary pressures in the largest cohort of patients with ApHCM at a single tertiary center. A total of 542 patients diagnosed with ApHCM were identified using ICD codes and clinical notes searches, confirmed by cross-referencing with cardiac MRI reports extracted through Natural Language Processing and through manual evaluation of patient charts and imaging records.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In 414 patients, echocardiogram measurements of pulmonary artery systolic pressure (PASP) were obtained at the time of diagnosis. The mean age was 59.4\u2009\u00b1\u200916.6 years, with 181 (44%) being females. The mean PASP was 38\u2009\u00b1\u200912\u2005mmHg in females vs. 33\u2009\u00b1\u20099\u2005mmHg in males (<jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.0001). PH as defined by a PASP value of &amp;gt;\u200936\u2005mmHg was present in 140\/414 (34%) patients, with a predominance in females [79\/181 (44%)] vs. males [61\/233 (26%), <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.0001]. Female sex, atrial fibrillation, diagnosis of congestive heart failure, and elevated filling pressures on echocardiogram remained significantly associated with PH (PASP\u2009&amp;gt;\u200936\u2005mmHg) in multivariable modeling. PH, when present, was independently associated with mortality [hazard ratio 1.63, 95% CI (1.05\u20132.53), <jats:italic>p<\/jats:italic>\u2009=\u20090.028] and symptoms [odds ratio 2.28 (1.40, 3.71), <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001].<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>PH was present in 34% of patients with ApHCM at diagnosis, with female sex predominance. PH in ApHCM was associated with symptoms and increased mortality.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2023.1288747","type":"journal-article","created":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T05:11:40Z","timestamp":1704949900000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Prevalence, sex differences, and implications of pulmonary hypertension in patients with apical hypertrophic cardiomyopathy"],"prefix":"10.3389","volume":"10","author":[{"given":"Vidhu","family":"Anand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan K.","family":"Covington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ushasi","family":"Saraswati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher G.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander T.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Frantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandan S.","family":"Anavekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey B.","family":"Geske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adelaide M.","family":"Arruda-Olson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle W.","family":"Klarich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.amjcard.2003.07.027","article-title":"Comparison of prevalence of apical hypertrophic cardiomyopathy in Japan and the United States","volume":"92","author":"Kitaoka","year":"2003","journal-title":"Am J Cardiol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e015294","DOI":"10.1161\/JAHA.119.015294","article-title":"Apical hypertrophic cardiomyopathy: the variant less known","volume":"9","author":"Hughes","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"B3","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.ijcard.2016.07.154","article-title":"Apical hypertrophic cardiomyopathy: present status","volume":"222","author":"Jan","year":"2016","journal-title":"Int J Cardiol"},{"key":"B4","first-page":"161","article-title":"Apical hypertrophic cardiomyopathy (apical hypertrophy): an overview","volume":"37","author":"Sakamoto","year":"2001","journal-title":"J Cardiol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.mayocp.2016.01.002","article-title":"The natural history of nonobstructive hypertrophic cardiomyopathy","volume":"91","author":"Hebl","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"B6","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/0735-1097(90)90180-W","article-title":"Apical hypertrophic cardiomyopathy: clinical follow-up and diagnostic correlates","volume":"15","author":"Webb","year":"1990","journal-title":"J Am Coll Cardiol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1016\/j.amjcard.2013.02.040","article-title":"Risk of death in long-term follow-up of patients with apical hypertrophic cardiomyopathy","volume":"111","author":"Klarich","year":"2013","journal-title":"Am J Cardiol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1093\/ehjci\/jew024","article-title":"Pulmonary hypertension is associated with worse survival in hypertrophic cardiomyopathy","volume":"17","author":"Ong","year":"2016","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"B9","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.ijcard.2017.07.010","article-title":"Pulmonary hypertension and clinical correlates in hypertrophic cardiomyopathy","volume":"248","author":"Musumeci","year":"2017","journal-title":"Int J Cardiol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.3760\/cma.j.issn.0253-3758.2016.12.004","article-title":"Prevalence of pulmonary hypertension in patients with hypertrophic obstructive cardiomyopathy: a case-control study","volume":"44","author":"Wu","year":"2016","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"key":"B11","doi-asserted-by":"publisher","first-page":"100398","DOI":"10.1016\/j.cpcardiol.2018.10.002","article-title":"Significance of pulmonary hypertension in hypertrophic cardiomyopathy","volume":"45","author":"Mitra","year":"2020","journal-title":"Curr Probl Cardiol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3434","DOI":"10.1093\/eurheartj\/ehx527","article-title":"Women with hypertrophic cardiomyopathy have worse survival","volume":"38","author":"Geske","year":"2017","journal-title":"Eur Heart J"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1016\/j.amjcard.2011.07.024","article-title":"Clinical and echocardiographic predictors of outcomes in patients with apical hypertrophic cardiomyopathy","volume":"108","author":"Moon","year":"2011","journal-title":"Am J Cardiol"},{"key":"B14","first-page":"521","article-title":"Diastolic dysfunction grading, echocardiographic and electrocardiogram findings in 50 patients with apical hypertrophic cardiomyopathy","volume":"74","author":"Aslannif","year":"2019","journal-title":"Med J Malaysia"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e004814","DOI":"10.1136\/bmjopen-2014-004814","article-title":"How does morphology impact on diastolic function in hypertrophic cardiomyopathy? A single centre experience","volume":"4","author":"Finocchiaro","year":"2014","journal-title":"BMJ Open"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e014448","DOI":"10.1161\/JAHA.119.014448","article-title":"Sex, survival, and cardiomyopathy: differences between men and women with hypertrophic cardiomyopathy","volume":"8","author":"Siontis","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"B17","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1159\/000517618","article-title":"Gender-Related differences in hypertrophic cardiomyopathy: a systematic review and meta-analysis","volume":"9","author":"Trongtorsak","year":"2021","journal-title":"Pulse (Basel)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1093\/eurheartj\/ehp297","article-title":"Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)","volume":"30","author":"Gali\u00e8","year":"2009","journal-title":"Eur Heart J"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.echo.2012.10.009","article-title":"Echocardiography in pulmonary arterial hypertension: from diagnosis to prognosis","volume":"26","author":"Bossone","year":"2013","journal-title":"J Am Soc Echocardiogr"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1801897","DOI":"10.1183\/13993003.01897-2018","article-title":"Pulmonary hypertension due to left heart disease","volume":"53","author":"Vachi\u00e9ry","year":"2019","journal-title":"Eur Respir J"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1016\/j.jacc.2020.03.064","article-title":"Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy","volume":"75","author":"Ho","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1080\/14656566.2023.2219840","article-title":"Current and emerging pharmacotherapy for the management of hypertrophic cardiomyopathy","volume":"24","author":"Rosenzveig","year":"2023","journal-title":"Expert Opin Pharmacother"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1288747\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T05:11:46Z","timestamp":1704949906000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1288747\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,11]]},"references-count":22,"alternative-id":["10.3389\/fcvm.2023.1288747"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2023.1288747","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,11]]},"article-number":"1288747"}}